No CrossRef data available.
Article contents
New drugs in the treatment of tobacco addiction
Published online by Cambridge University Press: 16 April 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and aims:
Both psychotherapy and pharmacotherapy approaches are needed to a successful treatment of tobacco addiction. Until now, bupropion and nicotine substitutes where the more important pharmacological agents, but things are becoming to change.
Methods:
The authors make a review about the new drugs available.
Results:
Varenicline tartrate has been approved by FDA in May of 2006, and preliminary studies of efficacy reveal percentages of tobacco cessation even higher than bupropion. Rimonabant is another new drug with potential utility in tobacco addiction. It is the first selective blocker of canabinoid receptors CB1. Selegiline and Topiramate can be useful in cases of comorbidity or resistance to other drugs, but they need more studies to establish their utility in treatment of tobacco addiction. Antinicotine vaccines are also been discussed, because they could reduce the cerebral distribution of nicotine, and then act in the positive reinforcement of tobacco addiction.
Conclusions:
Varenicline and rimonabant are two promising drugs in farmacological treatment of tobacco addiction
- Type
- Poster Session 1: Alcoholism and Other Addictions
- Information
- European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S186
- Copyright
- Copyright © European Psychiatric Association 2007
You have
Access
Comments
No Comments have been published for this article.